{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "INBX",
  "name": "Inhibrx Biosciences, Inc.",
  "url": "https://frontierpicks.com/dossiers/INBX/",
  "json_url": "https://frontierpicks.com/dossiers/INBX.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "Non-dilutive bridge into the 2027-04-14 PDUFA, with one item pulled forward: the 2026-08-13 Q2 release moved the INBRX-106 HNSCC PFS readout into Q3 2026 and dated the CRC registrational FDA meeting to Q4 2026. But the two-week advance from $88.66 (2026-08-07) to $103.63 (2026-08-21) carries no headline, and RSI(14) is 72.2.",
  "invalidation_trigger": "A weekly close below $88 gives back the entire post-Q2 advance and returns the name to the June-August shelf ($88.66 close 2026-08-07, $87.01 close 2026-06-05); secondarily 2026-09-30 passing with neither the guided Q3 HNSCC PFS readout nor a HexAgon Phase 3 initiation announced, or an S-3/ATM supplement filed.",
  "catalyst_date": null,
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "precision-biotech-therapeutics",
    "binary-catalyst-biotech",
    "oncology-immunology"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Thin share count: 15.7M weighted basic and diluted shares in Q2 2026 - 8-10% daily ranges are ordinary and single headlines can gap the stock.",
    "Capital structure is debt-heavy and equity-negative: $176.3M long-term debt and a $(53.0)M stockholders' deficit at 2026-06-30, before the July Term C draw is reflected.",
    "The $225.0M Term D tranche is drawable at the lenders' discretion in increments of $50.0M or more - an option the lenders hold, not committed capital.",
    "Sell-side coverage is roughly two to three analysts; published targets were set after spring 2026 data and have not been re-marked to the current tape.",
    "The defining regulatory decision is the 2027-04-14 PDUFA goal date for ozekibart in conventional chondrosarcoma; every interim item is company-guided cadence, not a regulatory clock."
  ],
  "body_markdown": "\n_Price reference: last completed daily close $103.63 (2026-08-21); 52-week high $141.84; RSI(14) 72.2._\n\n## INBX — Inhibrx Biosciences, Inc.\n\n## Current Thesis\nThe wait for the 2027-04-14 PDUFA got shorter at the front end. In the 2026-08-13 Q2 release Inhibrx moved the INBRX-106 progression-free-survival readout in first-line PD-L1-high head-and-neck cancer into Q3 2026 — it had been guided to Q4 2026 on 2026-05-11 — and dated the FDA meeting on a registrational colorectal design to Q4 2026, with interim data from the two new CRC Phase 1 cohorts in Q1 2027. The print itself was thin: net loss $36.7M, $(2.34) per share on 15.7M weighted shares, R&D $23.9M, G&A $8.3M, and shares fell 8.91% that day. What followed had no company release behind it — the stock closed $88.66 on 2026-08-07 and $103.63 on 2026-08-21, with RSI(14) at 72.2 and the name still 26.9% under the $141.84 52-week high. The narrative leg an investor is buying is a levered, non-dilutive bridge into an approval decision, with one guided data point arriving inside the quarter.\n\n## Bull Case\n- **Cash question answered for now.** Cash and equivalents were $133.3M at 2026-06-30 and $219.5M as of 2026-08-06 after the $100.0M Oxford Term C draw funded in July. The second amendment provides an additional $325.0M gross, with up to $225.0M drawable in increments of $50.0M or more (Q2 release, 2026-08-13).\n- **The share count did not move to pay for it.** 15.7M basic and diluted weighted shares in Q2;\n- **A dated readout was pulled forward, not pushed.** PFS from the HNSCC Phase 2 is now guided to Q3 2026 versus Q4 2026 at the 2026-05-11 disclosure. That disclosure showed 44.0% confirmed ORR with three complete responses versus 21.4% and none for pembrolizumab alone (n=53 evaluable).\n- **Filing gate stays clean.** FDA accepted the ozekibart BLA in conventional chondrosarcoma on 2026-06-15 with no filing review issues identified; PDUFA goal date 2027-04-14.\n- **Colorectal optionality is now enrolling, not conceptual.** Two additional Phase 1 CRC cohorts were initiated in Q2 2026 — ozekibart plus FOLFIRI/Avastin in second line, plus Lonsurf/Avastin in third/fourth line — with interim results guided to Q1 2027.\n\n## Bear Case\n- **The August advance has no headline under it.** The only INBX item in the month is the 2026-08-13 results release, and the stock closed down 8.91% on it. Everything from there to the $103.63 close on 2026-08-21 is flow through a share count under 16M.\n- **The balance sheet is a deficit.** Stockholders' deficit of $(53.0)M and long-term debt of $176.3M at 2026-06-30 — before the July draw is reflected. Term D is at the lenders' discretion in $50.0M increments, an option the lenders hold.\n- **The Q2 release did not restate a HexAgon Phase 3 start.** Initiation had been guided to Q3 2026 on 2026-05-11; no initiation announcement had been published as of 2026-08-21.\n- **Operating spend is rising into the wait.** R&D $23.9M versus $22.3M a year earlier; G&A $8.3M versus $6.4M. No cash-runway statement accompanied the Q2 release.\n- **Coverage is two to three analysts with targets set off spring data** — a $230–325 range on one aggregator, unmarked against a tape a fraction of that.\n\n## Setup & Price Structure\nThe three-month price change is +2.3%, up from the deeply negative reading that accompanied the June–July drift, which places the current tape at the upper edge of a range that has contained the name since the 2026-06-05 close of $87.01. The 2026-08-07 close of $88.66 marks the low shelf of that range; $103.63 on 2026-08-21 is roughly the June post-acceptance zone re-tested from below. RSI(14) at 72.2 is the highest reading in this note's coverage window and sits against a 26.9% gap to the $141.84 52-week high, so the move is momentum inside a range rather than a breakout to new highs.\n\nPositioning observables, stated as observables: the advance ran two weeks with no company release after 2026-08-13; the lender warrants struck at $93.21 are below the last close and immediately exercisable; the weighted share count of 15.7M supports 8–10% single-session moves on ordinary news, as the print day showed; and no equity offering, ATM or S-3 supplement had been announced, with no filings in the window checked. The overbought reading plus an undated-but-imminent PFS readout is the crowding evidence a reader should weigh — the catalyst window is open, but the entry point is at the top of the range and after the run.\n\nThe narrative is **maturing**. Attention peaked with the 2026-06-15 BLA acceptance and the 2026-07-16 financing; both are known, priced and behind the tape. The story still works — price is higher over two weeks — but the flow is moderating, coverage is not expanding, and nothing new has been introduced since 2026-08-13. It is not accelerating because no fresh headline dates the advance; it is not saturated because coverage remains two to three analysts and mainstream attention has not arrived.\n\n## Catalyst Calendar (next 30 days)\n\n- **~2026-09-30 (est., \"Q3 2026\" per the 2026-08-13 release)** — INBRX-106 plus pembrolizumab Phase 2 PFS readout in 1L PD-L1-high HNSCC. The single dated-by-quarter item that could land inside the window; converts a 44.0% ORR into durability.\n- **~2026-09-30 (est.)** — HexAgon Phase 3 initiation, guided Q3 2026 on 2026-05-11 and not restated in the Q2 release. An announcement would put a registrational clock on the second asset.\n\n## Elapsed catalysts\n\n- No SEC filing, conference presentation or FDA action with a confirmed calendar date falls inside 30 days of 2026-08-22 on the public record checked. *(passed 4d ago)*\n\n## What Would Change Our Mind\nThe structure that matters is the June–August range floor, not the 52-week high. Giving back the entire August advance would say the move was flow and that the guided Q3 PFS readout is not being anticipated: a **weekly close below $88** returns the name to the shelf marked by the $88.66 close of 2026-08-07 and the $87.01 close of 2026-06-05, and re-opens the path toward the pre-spike zone.\n\nTwo non-price conditions carry the same weight. First, 2026-09-30 passing with neither the HNSCC PFS readout nor a HexAgon Phase 3 initiation announced would mean the company slipped guidance it had just pulled forward, leaving nothing dated before the Q4 2026 CRC FDA meeting. Second, an S-3 or ATM prospectus supplement, or a marketed equity offering, would contradict the entire non-dilutive-bridge frame that the July financing established. On the other side, a PFS curve that separates cleanly plus a Phase 3 start inside Q3 would re-date the story and argue the range is a base rather than a top.\n\n## Correlation Notes\n- Pre-revenue, single-decision biotech: the name trades with small-cap biotech risk appetite (XBI-type flow) and with rate expectations that set the financing window, but has no revenue line to link it to macro data.\n- INBRX-106's registrational path is a combination with pembrolizumab; any change in that agent's competitive standing or a partner-side strategy shift in 1L HNSCC feeds directly into the second pillar of the pipeline.\n- Both lead programs sit inside one company and one financing structure, so a safety or durability signal in either is not diversified by the other — the Oxford facility is secured against the same enterprise.\n- Regulatory-process headlines (FDA staffing, review-timeline policy, advisory-committee practice) transmit to the 2027-04-14 goal date independently of anything the company does.",
  "first_seen": "2026-04-23",
  "last_analyzed": "2026-08-22T09:18:17+00:00",
  "last_synthesized": "2026-08-22",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}